KaZaA Media Desktop(以下简称KMD)是美国Sharman网络公司开发的一款非常优秀的点对点文件共享交换工具，允许众多用户分享网上资源，此外，它还内嵌了微软的IE和媒体播放器，能够直接播放共享资源中的媒体文件。KMD的操作简单，并且内...KaZaA Media Desktop(以下简称KMD)是美国Sharman网络公司开发的一款非常优秀的点对点文件共享交换工具，允许众多用户分享网上资源，此外，它还内嵌了微软的IE和媒体播放器，能够直接播放共享资源中的媒体文件。KMD的操作简单，并且内置了强大的共享资源搜索功能，使用户可以快速地对想要的文件进行定位．并直接从其他用户的电脑中下载：同样的道理，用户也可以将自己的文件共享给其他用户；此外．这个Sharman公司网站还为其开发了专门的防火墙，并一直在改进其搜索内核。强大的功能使得KMD一经推出、就深受用户的喜爱，迄今为止已经拥有几千万用户，堪称世界上最大的P2P资源共享平台。展开更多
The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomi...The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomized controlled trials. We searched PubMed （1966- December 2011）, Embase （1974-December 2011） and the Cochrane Library Database （2011, Issue 12）. The assessed outcome measures were the change from baseline for the International Prostate Symptom Score （IPSS）, quality of life （QoL） score, peak urine maximum flow rate （Qmax）, QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Qmax（mean difference （MD）=-2.78, P〈O.O0001; MD=-O.42, P--O.O04; MD= 1.17, P〈O.OOOOl,respectively） and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score （IPSS： MD=- 1.14, P=O.02; QoL score： MD=-0.26, P=O.02） and inferior to the 0.2 mg tamsulosin group with respect to Qmax （MD=-0.85, P=O.01）. In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin.展开更多
文摘KaZaA Media Desktop(以下简称KMD)是美国Sharman网络公司开发的一款非常优秀的点对点文件共享交换工具，允许众多用户分享网上资源，此外，它还内嵌了微软的IE和媒体播放器，能够直接播放共享资源中的媒体文件。KMD的操作简单，并且内置了强大的共享资源搜索功能，使用户可以快速地对想要的文件进行定位．并直接从其他用户的电脑中下载：同样的道理，用户也可以将自己的文件共享给其他用户；此外．这个Sharman公司网站还为其开发了专门的防火墙，并一直在改进其搜索内核。强大的功能使得KMD一经推出、就深受用户的喜爱，迄今为止已经拥有几千万用户，堪称世界上最大的P2P资源共享平台。
文摘The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomized controlled trials. We searched PubMed （1966- December 2011）, Embase （1974-December 2011） and the Cochrane Library Database （2011, Issue 12）. The assessed outcome measures were the change from baseline for the International Prostate Symptom Score （IPSS）, quality of life （QoL） score, peak urine maximum flow rate （Qmax）, QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Qmax（mean difference （MD）=-2.78, P〈O.O0001; MD=-O.42, P--O.O04; MD= 1.17, P〈O.OOOOl,respectively） and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score （IPSS： MD=- 1.14, P=O.02; QoL score： MD=-0.26, P=O.02） and inferior to the 0.2 mg tamsulosin group with respect to Qmax （MD=-0.85, P=O.01）. In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin.
